NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

$73.83 +0.04 (+0.05 %)

(As of 04/24/2018 04:00 PM ET)

Previous Close$73.83

Today's Range$72.52 - $74.88

52-Week Range$62.56 - $93.50

Volume3.57 million shs

Average Volume1.92 million shs

Market Capitalization$10.66 billion

P/E Ratio20.51

Dividend YieldN/A

Beta1.05

About Henry Schein (NASDAQ:HSIC)

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.

Receive HSIC News and Ratings via Email

Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical & hospital equipment

Sub-IndustryHealth Care Distributors

SectorMedical

SymbolNASDAQ:HSIC

CUSIP80640710

Webwww.henryschein.com

Phone631-843-5500

Debt

Debt-to-Equity Ratio0.32%

Current Ratio1.45%

Quick Ratio0.76%

Price-To-Earnings

Trailing P/E Ratio20.51

Forward P/E Ratio18.05

P/E Growth1.69

Sales & Book Value

Annual Sales$12.46 billion

Price / Sales0.91

Cash Flow$5.1993 per share

Price / Cash14.20

Book Value$18.00 per share

Price / Book4.10

Profitability

EPS (Most Recent Fiscal Year)$3.60

Net Income$406.29 million

Net Margins3.26%

Return on Equity19.70%

Return on Assets7.80%

Miscellaneous

Employees22,000

Outstanding Shares154,310,000

How to Become a New Pot Stock Millionaire

Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Shares of Henry Schein split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein declared that its Board of Directors has approved a share buyback program on Tuesday, September 19th 2017, which allows the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 6.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its shares are undervalued.

How were Henry Schein's earnings last quarter?

Henry Schein Inc (NASDAQ:HSIC) released its quarterly earnings results on Tuesday, February, 20th. The company reported $0.97 earnings per share for the quarter, hitting analysts' consensus estimates of $0.97. The company earned $3.32 billion during the quarter, compared to the consensus estimate of $3.30 billion. Henry Schein had a net margin of 3.26% and a return on equity of 19.70%. The business's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.94 earnings per share. View Henry Schein's Earnings History.

When is Henry Schein's next earnings date?

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Henry Schein.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein updated its FY18 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus estimate of $3.99.

What price target have analysts set for HSIC?

19 brokerages have issued twelve-month price targets for Henry Schein's stock. Their predictions range from $71.00 to $109.00. On average, they expect Henry Schein's share price to reach $82.50 in the next twelve months. View Analyst Ratings for Henry Schein.

Are investors shorting Henry Schein?

Henry Schein saw a increase in short interest in April. As of April 13th, there was short interest totalling 21,095,702 shares, an increase of 6.5% from the March 30th total of 19,816,414 shares. Based on an average daily trading volume, of 1,470,012 shares, the days-to-cover ratio is currently 14.4 days. Currently, 14.0% of the shares of the stock are short sold.

Who are some of Henry Schein's key competitors?

Some companies that are related to Henry Schein include Zoetis (ZTS), Express Scripts (ESRX), Beximco Pharmaceuticals (BXP), Humana (HUM), Vertex Pharmaceuticals (VRTX), Boston Scientific (BSX), Baxter International (BAX), Illumina (ILMN), Takeda Pharmaceutical (TKPYY), Hospital Co. of America (HCA), Regeneron (REGN), Fresenius Medical Care (FMS), Essilor International (ESLOY), Astellas Pharma (ALPMY) and McKesson (MCK).

Who are Henry Schein's key executives?

Henry Schein's management team includes the folowing people:

Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 68)
Mr. James P. Breslawski, Vice Chairman & Pres (Age 64)
Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 61)
Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 65)
Ms. Karen Prange, Exec. VP (Age 54)

Has Henry Schein been receiving favorable news coverage?

Headlines about HSIC stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Henry Schein earned a media sentiment score of 0.12 on Accern's scale. They also gave media stories about the company an impact score of 45.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $73.83.

How big of a company is Henry Schein?

Henry Schein has a market capitalization of $10.66 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]

MarketBeat Community Rating for Henry Schein (HSIC)

Community Ranking:		1.7 out of 5 ()
Outperform Votes:		188 (Vote Outperform)
Underperform Votes:		367 (Vote Underperform)
Total Votes:		555

MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Henry Schein (NASDAQ:HSIC) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Henry Schein in the last 12 months. Their average twelve-month price target is $82.0625, suggesting that the stock has a possible upside of 11.15%. The high price target for HSIC is $102.00 and the low price target for HSIC is $71.00. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.42	2.39	2.47	2.38
Ratings Breakdown:	1 Sell Rating(s) 9 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 9 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 10 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$82.0625	$82.3125	$84.2308	$92.8929
Price Target Upside:	11.15% upside	22.62% upside	16.76% upside	9.89% upside

Henry Schein (NASDAQ:HSIC) Consensus Price Target History

Price Target History for Henry Schein (NASDAQ:HSIC)

Henry Schein (NASDAQ:HSIC) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/24/2018	Northcoast Research	Set Price Target	Buy	$102.00	N/A
4/24/2018	Deutsche Bank	Boost Price Target	Buy -> Buy	$79.00 -> $82.00	High
4/24/2018	Goldman Sachs	Downgrade	Buy -> Neutral		High
4/4/2018	Leerink Swann	Upgrade	Market Perform -> Outperform	$75.00	High
3/8/2018	Barclays	Initiated Coverage	Equal Weight -> Equal Weight	$71.00	Low
2/27/2018	Bank of America	Initiated Coverage	Neutral -> Neutral	$76.00	Low
2/21/2018	Barrington Research	Reiterated Rating	Outperform		Low
2/15/2018	JPMorgan Chase	Reiterated Rating	Neutral -> Neutral	$79.00 -> $77.00	Low
1/4/2018	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$81.00	Medium
12/27/2017	Piper Jaffray	Reiterated Rating	Buy	$78.00	Low
12/6/2017	Morgan Stanley	Downgrade	Equal Weight -> Underweight	$88.00	High
11/28/2017	Credit Suisse Group	Reiterated Rating	Neutral	$87.50 -> $80.00	Low
11/28/2017	Stephens	Initiated Coverage	Equal -> Equal Weight	$76.00	Low
11/7/2017	Jefferies Group	Lower Price Target	Hold	$89.00 -> $74.00	N/A
11/7/2017	Stifel Nicolaus	Lower Price Target	Hold -> Hold	$89.00 -> $77.00	N/A
11/7/2017	Craig Hallum	Upgrade	Hold -> Buy		N/A
11/7/2017	Royal Bank of Canada	Lower Price Target	Sector Perform -> Sector Perform	$91.00 -> $82.00	N/A
10/19/2017	Robert W. Baird	Set Price Target	Buy	$95.00	N/A
9/15/2017	UBS	Reiterated Rating	Buy		N/A
1/10/2017	Gabelli	Upgrade	Hold -> Buy	$104.00	N/A

(Data available from 4/24/2016 forward)

Henry Schein (NASDAQ:HSIC) Earnings History and Estimates Chart

Earnings by Quarter for Henry Schein (NASDAQ:HSIC)

Henry Schein (NASDAQ:HSIC) Earnings Estimates

2018 EPS Consensus Estimate: $4.09
2019 EPS Consensus Estimate: $4.49

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	6	$0.91	$0.96	$0.93
Q2 2018	6	$0.92	$1.02	$0.99
Q3 2018	6	$1.00	$1.12	$1.03
Q4 2018	6	$1.09	$1.18	$1.14
Q1 2019	2	$1.02	$1.04	$1.03
Q2 2019	2	$1.02	$1.10	$1.06
Q3 2019	2	$1.12	$1.22	$1.17
Q4 2019	2	$1.21	$1.24	$1.23

Henry Schein (NASDAQ HSIC) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		$0.92					N/A
2/20/2018	Q4 2017	$0.97	$0.97	$3.3037 billion	$3.3181 billion	View	Listen
11/6/2017	Q3 2017	$0.90	$0.87	$3.0496 billion	$3.1611 billion	View	N/A
8/8/2017	Q2 17	$0.8650	$0.8750	$3.0525 billion	$3.0595 billion	View	Listen
5/9/2017	Q1 17	$0.8250	$0.88	$2.8334 billion	$2.9230 billion	View	Listen
2/21/2017	Q416	$0.9250	$0.94	$3.08 billion	$3.1209 billion	View	Listen
11/2/2016	Q316	$0.8250	$0.84	$2.88 billion	$2.8652 billion	View	N/A
8/4/2016	Q216	$0.8150	$0.82	$2.85 billion	$2.87 billion	View	N/A
5/3/2016	Q116	$0.6950	$0.7050	$2.66 billion	$2.70 billion	View	Listen
2/10/2016	Q415	$0.8250	$0.8350	$2.82 billion	$2.90 billion	View	Listen
11/4/2015	Q315	$0.7350	$0.7750	$2.70 billion	$2.70 billion	View	Listen
7/29/2015	Q215	$0.73	$0.73	$2.68 billion	$2.60 billion	View	Listen
5/4/2015	Q1	$0.6350	$0.64	$2.54 billion	$25.00 billion	View	Listen
2/11/2015	Q414	$0.7550	$0.78	$2.72 billion	$2.70 billion	View	Listen
11/6/2014	Q314	$0.6550	$0.67	$2.55 billion	$2.6237 billion	View	Listen
8/4/2014	Q214	$0.6650	$0.6750	$2.56 billion	$2.60 billion	View	Listen
5/6/2014	Q1	$0.5650	$0.59	$2.43 billion	$2.40 billion	View	Listen
2/11/2014	Q413	$0.6950	$0.7150	$2.53 billion	$2.50 billion	View	Listen
11/5/2013	Q313	$0.6050	$0.61	$2.37 billion	$2.30 billion	View	Listen
8/6/2013	Q2 2013	$0.6150	$0.6150	$2.39 billion	$2.40 billion	View	Listen
5/7/2013	Q1 2013	$0.5350	$0.53	$2.25 billion	$2.30 billion	View	Listen
2/13/2013	Q4 2012	$0.6050	$0.63	$2.40 billion	$2.40 billion	View	Listen
11/7/2012	Q312	$0.5350	$0.54	$2.24 billion	$2.2311 billion	View	N/A
8/2/2012		$0.55	$0.5550			View	N/A
5/8/2012		$0.46	$0.49			View	N/A
2/15/2012		$0.56	$0.5750			View	N/A
11/1/2011		$0.50	$0.4950			View	N/A
8/2/2011		$0.50	$0.5050			View	N/A
5/3/2011		$0.40	$0.41			View	N/A
2/22/2011		$0.48	$0.50			View	N/A
10/29/2010	Q3 2010	$0.44	$0.47			View	N/A
8/2/2010	Q2 2010	$0.43	$0.45			View	N/A
5/4/2010	Q1 2010	$0.35	$0.37			View	N/A
2/23/2010	Q4 2009	$0.46	$0.47			View	N/A
11/4/2009	Q3 2009	$0.41	$0.40			View	N/A
8/4/2009	Q2 2009	$0.38	$0.41			View	N/A
5/4/2009	Q1 2009	$0.29	$0.32			View	N/A
2/24/2009	Q4 2008	$0.44	$0.45			View	N/A
11/5/2008	Q3 2008	$0.38	$0.39			View	N/A
8/5/2008	Q2 2008	$0.34	$0.36			View	N/A
5/6/2008	Q1 2008	$0.28	$0.28			View	N/A
2/25/2008	Q4 2007	$0.41	$0.42			View	N/A

(Earnings results data provided by Zacks Investment Research)

Henry Schein (NASDAQ:HSIC) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Henry Schein (NASDAQ HSIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.19%
Institutional Ownership Percentage: 96.49%

Insider Trading History for Henry Schein (NASDAQ:HSIC)

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Henry Schein (NASDAQ HSIC) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2017	Barry J Alperin	Director	Sell	5,796	$70.76	$410,124.96	48,172
9/6/2017	Paul Rose	SVP	Sell	2,126	$172.51	$366,756.26	17,841
5/11/2017	Gerald A Benjamin	EVP	Sell	12,578	$175.10	$2,202,407.80	44,061
3/23/2017	Lorelei Mcglynn	SVP	Sell	9,300	$171.76	$1,597,368.00	33,048
3/20/2017	Michael Racioppi	SVP	Sell	9,969	$171.69	$1,711,577.61	33,057
3/17/2017	Mark E Mlotek	EVP	Sell	5,559	$170.98	$950,477.82	40,426
3/8/2017	James A Harding	SVP	Sell	10,552	$171.60	$1,810,723.20	21,118
3/8/2017	Philip A Laskawy	Director	Sell	1,103	$171.51	$189,175.53	13,872
3/2/2017	Michael S Ettinger	SVP	Sell	6,960	$171.09	$1,190,786.40	31,308
2/27/2017	Donald J Kabat	Director	Sell	4,334	$173.62	$752,469.08	10,729
2/22/2017	Paul Rose	SVP	Sell	6,821	$173.24	$1,181,670.04	24,674
2/22/2017	Steven Paladino	CFO	Sell	13,072	$173.40	$2,266,684.80	76,433
12/12/2016	Kurt P Kuehn	Director	Buy	1,000	$151.41	$151,410.00	2,039
11/3/2016	Mark E Mlotek	EVP	Sell	2,417	$155.19	$375,094.23	40,456
8/29/2016	Paul Brons	Director	Sell	3,381	$164.03	$554,585.43	13,715
6/2/2016	Gerald A Benjamin	EVP	Sell	9,991	$175.08	$1,749,224.28	54,885
5/16/2016	James A Harding	SVP	Sell	10,302	$172.60	$1,778,125.20	21,933
5/12/2016	Peter M Mccarthy	Insider	Sell	1,158	$171.75	$198,886.50	12,285
3/15/2016	Lonnie Shoff	CEO	Sell	3,028	$168.29	$509,582.12	31,000
3/14/2016	David Mckinley	Insider	Sell	3,339	$167.92	$560,684.88	27,645
3/14/2016	Norman S Matthews	Director	Sell	5,335	$167.75	$894,946.25	15,425
3/10/2016	Donald J Kabat	Director	Sell	1,218	$168.38	$205,086.84	3,189
3/7/2016	Barry J Alperin	Director	Sell	1,635	$167.36	$273,633.60	24,322
3/7/2016	Michael S Ettinger	SVP	Sell	5,423	$168.13	$911,768.99	32,286
3/4/2016	Philip A Laskawy	Director	Sell	1,317	$166.88	$219,780.96	17,294
3/2/2016	Louis W Sullivan	Director	Sell	11,735	$168.59	$1,978,403.65	16,830
3/2/2016	Mark E Mlotek	EVP	Sell	4,982	$167.93	$836,627.26	45,149
2/26/2016	Barry J Alperin	Director	Sell	7,540	$167.96	$1,266,418.40	33,294
2/24/2016	Robert Minowitz	Insider	Sell	9,648	$165.48	$1,596,551.04	25,788
2/22/2016	Michael Racioppi	SVP	Sell	21,567	$166.74	$3,596,081.58	49,866
2/17/2016	Stanley Komaroff	Insider	Sell	8,000	$163.53	$1,308,240.00	31,694
2/16/2016	Norman S Matthews	Director	Sell	4,230	$160.05	$677,011.50	17,122
2/12/2016	Steven Paladino	CFO	Sell	11,727	$157.21	$1,843,601.67	83,602
2/11/2016	Donald J. Kabat	Director	Sell	6,637	$156.36	$1,037,761.32	5,938
12/17/2015	Michael Racioppi	SVP	Sell	9,901	$155.92	$1,543,763.92	28,299
12/10/2015	Stanley M. Bergman	CEO	Sell	61,800	$155.45	$9,606,810.00	152,926
11/9/2015	Paul Rose	SVP	Sell	3,638	$151.92	$552,684.96	19,223
11/5/2015	Mark E. Mlotek	EVP	Sell	2,952	$155.00	$457,560.00	46,116
11/5/2015	Stanley Komaroff	Insider	Sell	6,297	$154.89	$975,342.33	39,694
9/16/2015	Philip A Laskawy	Director	Sell	4,000	$136.20	$544,800.00	16,191
5/6/2015	Paul Brons	Director	Sell	3,801	$136.70	$519,596.70
3/19/2015	Michael S Ettinger	SVP	Sell	4,352	$139.75	$608,192.00
3/18/2015	James P Breslawski	CEO	Sell	12,811	$139.45	$1,786,493.95
3/17/2015	Leonard A David	SVP	Sell	3,935	$140.00	$550,900.00
3/16/2015	Paul Rose	SVP	Sell	3,264	$140.13	$457,384.32
3/13/2015	Norman S Matthews	Director	Sell	9,200	$136.07	$1,251,844.00
3/11/2015	Philip A Laskawy	Director	Sell	2,669	$136.60	$364,585.40
3/10/2015	Donald J Kabat	Director	Sell	2,002	$138.00	$276,276.00
3/5/2015	Barry J Alperin	Director	Sell	6,637	$140.64	$933,427.68
2/24/2015	Stanley Komaroff	Insider	Sell	8,000	$141.69	$1,133,520.00
2/12/2015	Donald J Kabat	Director	Sell	5,000	$142.68	$713,400.00
2/12/2015	Gerald A Benjamin	EVP	Sell	22,116	$142.71	$3,156,174.36
2/12/2015	Robert Minowitz	Insider	Sell	11,254	$142.63	$1,605,158.02
12/18/2014	Leonard A David	SVP	Sell	3,557	$135.34	$481,404.38
12/9/2014	Stanley M Bergman	CEO	Sell	69,600	$135.56	$9,434,976.00
12/8/2014	Stanley M Bergman	CEO	Sell	23,485	$136.34	$3,201,944.90
11/24/2014	Stanley Komaroff	Insider	Sell	13,757	$133.06	$1,830,506.42
11/7/2014	Lorelei Mcglynn	SVP	Sell	15,746	$129.03	$2,031,706.38
11/7/2014	Mark E Mlotek	EVP	Sell	6,262	$128.75	$806,232.50
9/2/2014	Philip A Laskawy	Director	Sell	15,438	$119.40	$1,843,297.20
8/29/2014	Louis W Sullivan	Director	Sell	17,262	$119.99	$2,071,267.38
6/9/2014	Barry J Alperin	Director	Sell	7,500	$120.39	$902,925.00
6/2/2014	Gerald A Benjamin	EVP	Sell	12,354	$119.50	$1,476,303.00
5/28/2014	Norman S Matthews	Director	Sell	6,637	$118.68	$787,679.16
5/19/2014	Donald Kabat	Director	Sell	5,000	$116.30	$581,500.00	8,851
5/15/2014	Paul Brons	Director	Sell	5,363	$113.77	$610,148.51	13,851
3/19/2014	Barry Alperin	Director	Sell	7,500	$119.18	$893,850.00	25,104
3/17/2014	Lonnie Shoff	CEO	Sell	3,722	$119.06	$443,141.32	31,267
3/12/2014	Michael Ettinger	SVP	Sell	3,537	$119.20	$421,610.40	31,760
3/11/2014	David Mckinley	Insider	Sell	2,387	$119.65	$285,604.55	28,526
3/11/2014	James Breslawski	CEO	Sell	72,642	$119.35	$8,669,822.70	113,936
3/11/2014	Paul Rose	SVP	Sell	3,783	$119.72	$452,900.76	20,229
3/10/2014	Robert Minowitz	Insider	Sell	11,553	$119.98	$1,386,128.94	27,756
3/4/2014	Donald Kabat	Director	Sell	5,000	$119.15	$595,750.00	12,159
2/28/2014	Michael Racioppi	SVP	Sell	18,614	$118.91	$2,213,390.74	30,667
2/26/2014	Stanley Komaroff	Insider	Sell	18,000	$119.36	$2,148,480.00	59,796
2/25/2014	Mark Mlotek	EVP	Sell	20,333	$119.16	$2,422,880.28	52,899
2/20/2014	Steven Paladino	CFO	Sell	28,757	$117.79	$3,387,287.03	88,276
2/12/2014	Philip Laskawy	Director	Sell	5,851	$114.91	$672,338.41	15,982
12/19/2013	Mark Mlotek	EVP	Sell	22,004	$111.97	$2,463,787.88	53,454
12/19/2013	Michael Racioppi	SVP	Sell	29,257	$111.97	$3,275,906.29	26,036
12/17/2013	Gerald Benjamin	EVP	Sell	41,664	$111.66	$4,652,202.24	66,887
12/17/2013	James Breslawski	CEO	Sell	57,754	$111.91	$6,463,250.14	118,030
12/16/2013	Steven Paladino	CFO	Sell	47,652	$112.31	$5,351,796.12	88,276
12/13/2013	Stanley Bergman	CEO	Sell	78,000	$111.90	$8,728,200.00	163,770
12/6/2013	Leonard David	SVP	Sell	13,968	$113.14	$1,580,339.52	20,620
11/26/2013	Stanley Komaroff	Insider	Sell	22,329	$114.79	$2,563,145.91	59,796
8/23/2013	Philip Laskawy	Director	Sell	21,637	$103.17	$2,232,289.29	21,833
8/22/2013	Norman Matthews	Director	Sell	9,851	$103.95	$1,024,011.45	21,782
8/20/2013	Louis Sullivan	Director	Sell	15,000	$103.91	$1,558,650.00	20,987
8/12/2013	Donald Kabat	Director	Sell	2,500	$106.25	$265,625.00	10,598
6/18/2013	Barry J Alperin	Director	Sell	7,500	$97.74	$733,050.00
5/8/2013	James A Harding	CTO	Sell	12,000	$92.64	$1,111,680.00
3/8/2013	Donald J Kabat	Director	Sell	4,038	$90.00	$363,420.00
12/4/2012	Donald J Kabat	Director	Sell	15,000	$80.04	$1,200,600.00

(Data available from 1/1/2013 forward)

Henry Schein (NASDAQ HSIC) News Headlines

Source:

Date	Headline
	Henry Schein (HSIC) to Spin off and Merge its Animal Health Business with Vets First Choice - Slideshow seekingalpha.com - April 24 at 4:53 PM
	Henry Schein Move May Spur More Animal-Health Deals finance.yahoo.com - April 24 at 4:53 PM
	FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Henry Schein, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm finance.yahoo.com - April 24 at 4:53 PM
	EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Henry Schein, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 – HSIC finance.yahoo.com - April 24 at 4:53 PM
	Henry Schein (HSIC) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - April 24 at 12:16 PM
	Deutsche Bank Raises Henry Schein (HSIC) Price Target to $82.00 www.americanbankingnews.com - April 24 at 9:12 AM
	Henry Schein (HSIC) Downgraded by Goldman Sachs to Neutral www.americanbankingnews.com - April 24 at 8:54 AM
	Henry Schein Target of Unusually High Options Trading (HSIC) www.americanbankingnews.com - April 24 at 6:12 AM
	Akorn gets slammed, Henry Schein makes a deal, Merck snags double upgrade finance.yahoo.com - April 23 at 4:37 PM
	Henry Schein to spin off animal health unit www.reuters.com - April 23 at 8:57 AM
	Henry Schein plans animal health spinoff, expects more than $1 bln www.marketwatch.com - April 23 at 8:57 AM
	Henry Schein Animal Health To Merge With Vets First Choice - Quick Facts www.rttnews.com - April 23 at 8:57 AM
	Henry Schein to spin off and merge its animal health business with Vets First Choice seekingalpha.com - April 23 at 8:57 AM
	Henry Schein to spin off, merge its animal health business with start-up www.cnbc.com - April 23 at 6:50 AM
	Why the California Dental Association launched its own e-commerce platform finance.yahoo.com - April 20 at 9:21 AM
	SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Henry Schein, Inc. (HSIC) and Lead Plaintiff Deadline: May 7, 2018 finance.yahoo.com - April 18 at 4:56 PM
	Henry Schein, Inc. Financial Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and Directors finance.yahoo.com - April 18 at 4:56 PM
	INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Henry Schein, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - HSIC finance.yahoo.com - April 18 at 4:56 PM
	Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Filed Against Henry Schein, Inc. on Behalf of Shareholders finance.yahoo.com - April 18 at 4:56 PM
	Henry Schein (HSIC) Stock Rating Reaffirmed by Credit Suisse Group www.americanbankingnews.com - April 18 at 2:58 PM
	The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Henry Schein, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (HSIC) finance.yahoo.com - April 17 at 5:06 PM
	HSIC ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Henry ... www.prnewswire.com - April 17 at 9:34 AM
	HSIC ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Henry Schein, Inc. - HSIC finance.yahoo.com - April 16 at 4:37 PM
	Henry Schein, Inc. Awards Third Annual Henry Schein Cares Gold Medal To The Night Ministry finance.yahoo.com - April 16 at 9:05 AM
	Henry Schein, Inc. (HSIC) to Post Q1 2018 Earnings of $0.95 Per Share, Piper Jaffray Forecasts www.americanbankingnews.com - April 16 at 1:30 AM
	Henry Schein (HSIC) Upgraded to "Hold" at BidaskClub www.americanbankingnews.com - April 14 at 10:44 AM
	HENRY SCHEIN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess of $100000 of Lead ... www.businesswire.com - April 14 at 9:20 AM
	Henry Schein (HSIC) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 14 at 12:49 AM
	Analysts Anticipate Henry Schein, Inc. (HSIC) Will Announce Quarterly Sales of $3.17 Billion www.americanbankingnews.com - April 13 at 4:33 AM
	Northcoast Research Upgrades Henry Schein (HSIC) to "Buy" www.americanbankingnews.com - April 12 at 11:52 PM
	DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Henry Schein, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm finance.yahoo.com - April 12 at 4:42 PM
	EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Henry Schein, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - HSIC finance.yahoo.com - April 12 at 4:42 PM
	SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Henry Schein, Inc. (HSIC) & Lead Plaintiff Deadline: May 7, 2018 finance.yahoo.com - April 12 at 4:42 PM
	IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Henry Schein, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm finance.yahoo.com - April 12 at 10:00 AM
	DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Henry Schein, Inc. To Contact The Firm finance.yahoo.com - April 12 at 10:00 AM
	Henry Schein Names Christopher Pendergast To Lead Information Technology finance.yahoo.com - April 12 at 10:00 AM
	Henry Schein, Inc. (HSIC) Sees Large Increase in Short Interest www.americanbankingnews.com - April 12 at 2:17 AM
	Henry Schein (HSIC) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 11 at 8:26 PM
	INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Henry Schein, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - HSIC finance.yahoo.com - April 11 at 9:48 AM
	Henry Schein, Inc. (HSIC) Expected to Announce Earnings of $0.92 Per Share www.americanbankingnews.com - April 11 at 5:53 AM
	DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Henry Schein, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm finance.yahoo.com - April 10 at 9:36 AM
	Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program Receives 2018 William J. Gies Award finance.yahoo.com - April 10 at 9:36 AM
	Henry Schein Ties Up With Internet Brands to Boost Dental Arm www.zacks.com - April 9 at 9:25 AM
	Henry Schein Names Mark Hillebrandt Vice President, Marketing, North America Dental Group finance.yahoo.com - April 9 at 9:25 AM
	Q1 2018 EPS Estimates for Henry Schein, Inc. Increased by Analyst (HSIC) www.americanbankingnews.com - April 6 at 6:22 AM
	Henry Schein, Inc. (HSIC) Forecasted to Post Q2 2018 Earnings of $1.01 Per Share www.americanbankingnews.com - April 5 at 8:52 AM
	SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed Against Henry Schein, Inc. - HSIC finance.yahoo.com - April 4 at 4:48 PM
	EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Henry Schein, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 – HSIC finance.yahoo.com - April 4 at 4:48 PM
	Henry Schein (HSIC) Lifted to "Buy" at Leerink Swann www.americanbankingnews.com - April 4 at 8:04 AM
	Henry Schein, Inc. (HSIC) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - April 4 at 3:06 AM

Henry Schein (NASDAQ:HSIC) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Henry Schein (NASDAQ:HSIC) Income Statement, Balance Sheet and Cash Flow Statement

Henry Schein (NASDAQ HSIC) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff